Current scenario of cryptococcosis and antifungal susceptibility pattern in India: a cause for reappraisal

Mycoses
Malini Rajinder CapoorUma Banerjee

Abstract

This study analysed the spectrum, antifungal susceptibility pattern, clinical course and molecular epidemiology of cryptococcosis. Four hundred and thirty-nine samples obtained from 378 meningitis patients were processed by standard procedures. Minimum inhibitory concentration (MIC) of fluconazole and amphotericin B for the isolates was tested by broth micro dilution and by E-strip method. Molecular analysis by random amplified polymorphic DNA-PCR of eight isolates was performed using M13 primer. Cryptococcosis was diagnosed in 35 patients [HIV-1 seropositive (19) and apparently immunocompetent (16)]. Cryptococcus neoformans var. neoformans (serotype A and D) was the predominant isolate on phenotypic identification. Three C. neoformans var. gattii were isolated from HIV-1 seropositive (2) and apparently immunocompetent (1) patients. MIC 90 for amphotericin B and fluconazole were 1 and 8 mug ml(-1) respectively. On RAPD-PCR, less diversity was seen among Indian isolates. AIDS remains the single most important risk factor for cryptococcosis. Rising MIC of the available induction and maintenance drugs is of grave concern. The DNA typing technique showed less diversity among Indian strains. Routine surveillance and application of m...Continue Reading

References

May 1, 1992·Journal of Clinical Microbiology·E D Spitzer, S G Spitzer
May 19, 2000·Antimicrobial Agents and Chemotherapy·A I AllerA Espinel-Ingroff
Mar 29, 2001·Medical Mycology·U BanerjeeK Gupta
Oct 16, 2001·Antimicrobial Agents and Chemotherapy·M E BrandtUNKNOWN Cryptococcal Disease Active Surveillance Group
Feb 27, 2003·Emerging Infectious Diseases·Wieland MeyerUNKNOWN IberoAmerican Cryptococcal Study Group
Mar 11, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sara A MirzaRana A Hajjeh
Apr 14, 2004·Emerging Infectious Diseases·Lennox K ArchibaldGary W Procop
Aug 7, 2004·Journal of Clinical Microbiology·Adam JenneyBart J Currie
May 6, 2005·Journal of Clinical Microbiology·M A PfallerD J Diekema
Nov 8, 2005·Journal of Clinical Microbiology·N JainB C Fries
Dec 2, 2005·Emerging Infectious Diseases·Sudha ChaturvediVishnu Chaturvedi
Mar 1, 2006·QJM : Monthly Journal of the Association of Physicians·G LuiC S Cockram
Jun 28, 2006·Antimicrobial Agents and Chemotherapy·E DannaouiUNKNOWN French Cryptococcosis Study Group
Aug 30, 2006·Scandinavian Journal of Infectious Diseases·Chih-Jen YangMing-Shyan Huang

❮ Previous
Next ❯

Citations

Jul 27, 2010·Canadian Journal of Microbiology·José Júlio Costa SidrimMarcos Fábio Gadelha Rocha
Sep 13, 2011·Medical Mycology·Monica A Slavin, Arunaloke Chakrabarti
Sep 21, 2013·ISRN AIDS·Spinello Antinori
Jan 16, 2016·Fungal Genetics and Biology : FG & B·Massimo CogliatiAshok Varma
Feb 23, 2010·Enfermedades infecciosas y microbiología clínica·Estrella Martín Mazuelos, Ana Isabel Aller García
Aug 6, 2011·Mycoses·Massimo CogliatiMaria Anna Viviani
Sep 17, 2011·Mycopathologia·M CogliatiAnna Maria Tortorano
Dec 5, 2016·Medical Mycology·Navaporn WorasilchaiAriya Chindamporn
Jan 27, 2018·Journal of Fungi·Patricia F HerkertFlávio Queiroz-Telles
Jan 21, 2021·Mycopathologia·Immaculata XessAnupma Jyoti Kindo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.